What: Shares of Lexicon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of small-molecule treatments to fight a host of diseases, rocketed higher by as much as ...

A look at the shareholders of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX stock here.

CEO Michael Exton emphasized the company's focus on advancing R&D, stating, "We've successfully repositioned the company to really focus on R&D. We've achieved this focus by developing our innovative ...

Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these two companies, what’s moving them, and what’s next ...

MIKE: Also, a listener of Lexicon Valley wrote recently in an iTunes review that every time he or she listens to an episode of this show, "I find myself committing whatever linguistic solipsism was ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...

Lexicon Pharmaceuticals (LXRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2019. This widely-known consensus ...

An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...

Lexicon inks a major collaborative deal and reports a narrow than expected quarterly loss. All in a day's work for a daily top-performer. So what: Although it was the smaller of the two catalysts, ...